Drug Combination Shows Promise in Treating Pancreatic Tumors


This was a randomized, phase 2 clinical trial that compared the effects of temozolomide alone with those of temozolomide in combination with capecitabine. It included 144 patients.

Combination of capecitabine and temozolomide produced longer progression-free survival rates, higher response rates, and longer overall survival rates than temozolomide alone

.

Advertisement



In addition, deficiency of the DNA repair enzyme methylguanine methyltransferase (MGMT) in the tumor tissue, was found to be associated with increased responses.

This clinical trial is practice-changing and the combination of capecitabine and temozolomide should be included as a standard treatment option for patients with advanced pancreatic NETs,” said Kunz.

In addition, MGMT testing can be considered for select patients receiving temozolomide for whom the response is a primary goal of treatment. However, testing is not recommended for routine use as confirmatory studies are needed.”

The findings are part of the ECOG-ACRIN E2211 trial, conducted through the National Cancer Institute and the National Clinical Trial Network.

Source: Medindia



Source link